Form 8-K - Current report:
SEC Accession No. 0001193125-20-000245
Filing Date
2020-01-02
Accepted
2020-01-02 08:36:19
Documents
15
Period of Report
2020-01-02
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d856254d8k.htm   iXBRL 8-K 35797
2 EX-99.1 d856254dex991.htm EX-99.1 21300
7 GRAPHIC g856254g1227091036551.jpg GRAPHIC 4415
  Complete submission text file 0001193125-20-000245.txt   233749

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amgn-20200102.xsd EX-101.SCH 4547
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20200102_def.xml EX-101.DEF 13773
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20200102_lab.xml EX-101.LAB 22821
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20200102_pre.xml EX-101.PRE 14742
16 EXTRACTED XBRL INSTANCE DOCUMENT d856254d8k_htm.xml XML 6351
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 20500186
SIC: 2836 Biological Products, (No Diagnostic Substances)